The global AI in cancer immunotherapy drugs market size accounted for USD 2.80 billion in 2025 and is predicted to increase from USD 3.52 billion in 2026 to approximately USD 27.79 billion by 2035, expanding at a CAGR of 25.80% from 2026 to 2035. By AI technology, the machine learning segment held 34% of market share in 2025. By immunotherapy type, the immune checkpoint inhibitors segment held a major market share of 34% in 2025. By cancer type, the lung cancer segment held the largest market share of 24% in 2025. By application, the drug discovery segment led the market with a share of 25% in 2025. Roche launched the pharmaceutical industry's largest hybrid-cloud AI factory, powered by over 3,500 NVIDIA Blackwell GPUs. NVIDIA and Lilly are launching a USD 1 billion co-innovation lab over five years starting January 2026. AstraZeneca extended its AI partnership with Immunai through 2027 in a $37.5 million deal utilizing the AMICA-OS platform in May 2026. In December 2025, Syneron Bio secured nearly USD 100 million in Series A funding led by AstraZeneca and Pfizer, while Syremis Therapeutics launched with a USD 165 million Series A round. In February 2026, Philips and the PreciseOnco consortium secured a EUR 14